Please provide your email address to receive an email when new articles are posted on . Postmenopausal women assigned denosumab have increases in mineral to matrix ratio at the cortical and cancellous ...
Denosumab may reduce the risk of fracture in women with breast cancer on aromatase inhibitor therapy
denosumab breast cancer treatment Denosumab has been shown to reduce fracture risk in women with breast cancer with bone metastases. At baseline, 45% of women had low bone mineral density (BMD) with T ...
August 11, 2009 — Denosumab injections are associated with lower fracture rate in postmenopausal women with osteoporosis, according to the results of an international, randomized, double-blind, ...
Zoledronate infusion preserves BMD gains after denosumab discontinuation for women with osteoporosis
Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...
THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment ...
Prolia is approved in the U.S. for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for ...
Twice-yearly treatment with denosumab, a fully human monoclonal antibody, may be associated with increased bone mineral density (BMD) among patients who receive adjuvant aromatase inhibitors (AIs) ...
THOUSAND OAKS, Calif., June 1 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia ...
Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...
Denosumab is a fully human monoclonal antibody that targets RANKL (the receptor activator of nuclear factor κB ligand)—a protein that acts as the primary mediator of osteoclast differentiation, ...
Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab). Both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback